[Effects of 2, 3, 4', 5-tetrahydroxystilbene -2-O-beta-D glucoside on content of nitric oxide synthase and expression of nitric oxide synthase in artery vessels of experimental atherosclerotic rats].
OBJECTIVE
To investigate the effects of TSG on the content of nitric oxide synthase and the expression of endothelium nitric oxide synthase in artery vessels of experimental atherosclerotic rats.


METHODS
The atherosclerosis model of rat was made by feeding high grease food and injecting Vit D3. Sixty male rats were randomly divided into six groups: normal control; model control; TSG high dose; TSG middle dose; TSG low dose; Simvastatin. After 12 weeks, several aorta were randomly tested, and the model made was successful when we found plaque. And after six weeks of treatment, the levels of NOS in serum were measured with a biochemical method. The biochemical method was adopted to detect the content of nitric oxide synthase and half-quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to detect eNOS and iNOS gene expression in artery vessels.


RESULTS
Data of the study demonstrated that compared with model group, the activity of NOS and the gene expression of eNOS were increased remarkably, and however the gene expression of iNOS was reduced markedly in simvastatin group and TSG 60, 120 mg x kg(-1) x d(-1) group.


CONCLUSIONS
TSG can enhance the expression of eNOS gene and reduce the expression of iNOS gene in aorta vessels of experimental atherosclerotic rats, which may be one of the anti-atherosclerosis mechanisms of TSG.
Shen
Yan
Y
Department of Pharmacology, Nantong University, Nantong 226001, China.
Wang
Chun-Hua
CH
Wang
Yu-Qin
YQ
Li
Feng
F
Zhang
Wei
W
D000818:Animals; D001158:Arteries / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D050197:Atherosclerosis / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D005960:Glucosides / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D019001:Nitric Oxide Synthase / Q000235:genetics* / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use
D005960:Glucosides; D013267:Stilbenes; C093026:2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III